Navigation Links
Dendreon Announces Presentation of Data at American Urological,Association Annual Meeting

mized Phase 3 trials (D9901 and D9902A; n=225) conducted in men with asymptomatic, metastatic, androgen independent prostate cancer. Survival analyses were performed on the subgroup of 82 patients in the trials that were documented to have received docetaxel chemotherapy following initial treatment with either PROVENGE or placebo.

According to the analysis, the patients who received initial treatment with PROVENGE followed by docetaxel had a median survival of 34.5 months compared to 25.4 months for those patients in the placebo arm who received treatment with docetaxel chemotherapy, a 9.1 month difference. In addition, an analysis of overall survival demonstrated that patients in the PROVENGE arm who received subsequent therapy with docetaxel had a 47 percent reduction in their risk of death compared to those in the placebo arm who received subsequent therapy with docetaxel (HR = 1.90, p-value = 0.023).

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 218,890 new cases expected to be diagnosed in 2007, and more than 27,000 men expected to die this year from the disease.

About PROVENGE

PROVENGE (sipuleucel-T) is an investigational product that may represent the first in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to stimulate a patient's own immune system. PROVENGE is in late-stage clinical development for the treatment of patients with early-stage and advanced prostate cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the im
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company plc ... the Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder ... "Our views of Mylan,s offer to Perrigo ... based on our Board,s careful reflection of the value ... the limited choices that Mylan has allowed its shareholders ...
(Date:8/28/2015)... 28, 2015 The report "Eubiotics Market by Type ... Ruminant, and Aquaculture), & by Region ( North America ... , and Rest of the World) - Global Trends ... for Eubiotics was valued at USD 4.62 Billion in 2014 ... at a CAGR of 7.4% from 2015 to 2020. ...
(Date:8/27/2015)... , Aug. 27, 2015  A recent study ... Knee Journal, compared the Arthrosurface HemiCAP® Wave implant, ... versus an "onlay" design implant for isolated patellofemoral ... in function and pain scores, none of the ... osteoarthritis (OA). However, 53% of the patients in ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... Calif., March 15, 2011 XTIO2 INC ... -nominees with the XTI ANTI-GERM / ANTI-VOC / ... and XTI™  Nano-Facemask . It is the ... against germs transmitted via air and contact surfaces. The ...
... FRANCISCO, March 15, 2011 Motion Therapeutics, Inc. ... for balance and mobility disorders, today announced that researchers ... a NIH Recovery Act Grant to study the effects ... and mobility in people with MS. ...
Cached Medicine Technology:OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 2OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 3The Balance-Based Torso-Weighting® Treatment for Multiple Sclerosis Receives a NIH Recovery Act Grant 2
(Date:8/29/2015)... ... August 29, 2015 , ... ... two inventors from Miller Place, N.Y. "I specialize in manual therapy, and my ... addition, it can be used for additional muscle dysfunction throughout the body." , ...
(Date:8/29/2015)... ... 2015 , ... Dr. Tim Novelli, DC., Founder and President of the Patriot ... of the chiropractic field in the military. All too often VA hospitals treat patients ... made available to the VA program over a decade ago, the reality is that ...
(Date:8/29/2015)... ... , ... ProDrop Particles includes over 40 particle backdrops designed for use in ... that users can shrink and stretch in the Final Cut Pro X timeline. Choose ... brightness, scale, speed, range, and flare attributes with intuitive controls found in the top-right ...
(Date:8/29/2015)... ... August 29, 2015 , ... The popular television program VOICES IN ... announced that it will be devoting an entire short segment to the subject of ... around the globe on a daily basis, but recent advancements in medical science may ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a ... Memorial Hospital recently transitioned management companies to partner with Wound Care Advantage (WCA) ... outpatient wound center. , Transitioning wound care management providers can be a ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... Should physicians be banned from assisting in a lethal ... A recent ruling by the American Board of Anesthesiology ... punishment, and other medical boards may act similarly. An ... concludes that decertification of physicians participating in lethal ...
... HealthDay Reporter , THURSDAY, June 9 (HealthDay News) ... disease among kidney patients by as much as 25 percent, ... ever conducted. "People with kidney disease are at a ... Dr. Colin Baigent, a professor of epidemiology at the University ...
... in the Clinical Neuropsychologist (e-publication ahead of ... in the brain development of preschool children with symptoms ... the brain important for cognitive and motor control was ... Novel for its use of neuroimaging in very young, ...
... Sheffield,s School of Health and Related Research (ScHARR) has developed ... been accepted for use by the Department of Health. ... Jacques and James Fotheringham, were commissioned in January 2011 by ... index to look at deaths following a hospital admission. In ...
... , Bethesda, MD Vaccinating children around the world against ... past several decades. Now new opportunities exist to overcome remaining ... according articles in the June 2011 edition of Health ... from the Bill & Melinda Gates Foundation. Last ...
... into a wallet or pursebut it could mean the difference between ... stores personal medical data (e.g. information on existing medical conditions, allergies ... enabling the data to be accessed in just a few moments. ... have been trialled in the UK. This working prototype has ...
Cached Medicine News:Health News:Physician participation in lethal injection executions should not be banned, argue 2 ethicists 2Health News:Physician participation in lethal injection executions should not be banned, argue 2 ethicists 3Health News:Vytorin Lowers Heart Disease Risk in Large Study of Kidney Patients 2Health News:Vytorin Lowers Heart Disease Risk in Large Study of Kidney Patients 3Health News:Brain imaging study of preschoolers with ADHD detects brain differences linked to symptoms 2Health News:New hospital mortality rate index to be used across UK 2Health News:New hospital mortality rate index to be used across UK 3Health News:'Decade of vaccines' has potential to save lives, but challenges ahead 2Health News:'Decade of vaccines' has potential to save lives, but challenges ahead 3Health News:'Decade of vaccines' has potential to save lives, but challenges ahead 4Health News:MyCare -- the 'card' that could save your life 2
... knee system was designed to ... between all articulating surfaces and ... with wear in order to ... with normalized quadriceps and patellar ...
...
...
...
Medicine Products: